Jennifer Humes
Fortune : 4 M $ au 30/06/2026
Fortune : 4 M $ au 30/06/2026
Jennifer Humes is Chief Accounting Officer at Roivant Sciences Ltd. and Roivant Sciences, Inc., starting in 2025.
Ms. Humes worked at JPMorgan Chase & Co. from 2016 to 2024, serving as Controller-Global Investment Banking in 2024.
Ms. Humes completed undergraduate education at the University of St. Thomas.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 20/06/2026 | 109 782 ( 0,02% ) | 4 M $ | 30/06/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ROIVANT SCIENCES LTD. | Comptroller/Controller/Auditor | 20/02/2025 |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Comptroller/Controller/Auditor | 20/02/2025 |
| Sociétés | Poste | Fin |
|---|---|---|
| JPMORGAN CHASE & CO. | Corporate Officer/Principal | 01/12/2024 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 4 |
|---|---|
JPMorgan Chase & Co.
JPMorgan Chase & Co. Major BanksFinance Provides banking, asset management, investment banking, credit card and mortgage services | Finance |
Roivant Sciences Ltd.
Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
University of St. Thomas
University of St. Thomas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national